Zetiq Technologies

Company Overview

Snapshot

Founded in December 1997, Zetiq Technologies operates with 1–10 employees. The company was acquired by Micromedic in June 2011, leading to its current inactive status.

Business overview

Zetiq Technologies developed CellDetect, a proprietary platform for cancer detection that uses discriminate staining to differentiate cancer cells from normal cells while preserving their morphological features. This technology enables color discrimination, turning cancer cells red and non-cancer cells green. Zetiq offers dual-color and morphological diagnostic products through a simple in-vitro procedure, aiming to save resources and facilitate automation for various cancer indications. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Diagnostics Devices, targeting laboratories and healthcare providers in Europe and China.

Company Intelligence Q&A

What is Zetiq Technologies' primary product?

Zetiq Technologies' primary product is CellDetect, a proprietary platform designed for the detection of cancer cells through discriminate staining.

When was Zetiq Technologies founded?

Zetiq Technologies was founded in December 1997.

What is the core technology behind Zetiq Technologies' offerings?

The core technology is the CellDetect platform, which enables color discrimination by staining cancer cells red and non-cancer cells green, preserving cellular morphology for diagnostic purposes.

Which markets does Zetiq Technologies target?

Zetiq Technologies targets markets in Europe and China with its diagnostic products.

What was a significant corporate milestone for Zetiq Technologies?

Zetiq Technologies was acquired by Micromedic in June 2011, leading to its current inactive status as a wholly-owned subsidiary of Micromedic and BioLight.